← Patent-cliff monitor small molecule YUVIWEL NAVEPEGRITIDE
Loss of exclusivity November 2042 latest FDA-listed patent expiry
Company ASCENDIS PHARMA GROWTH DISORDERS AS
Drug detail Brand name YUVIWEL Active ingredient NAVEPEGRITIDE Strength 1.3MG/VIAL Dosage form POWDER Route SUBCUTANEOUS Modality Small molecule FDA approval February 2026 Marketing status RX
Listed patents Patent Expires Type 12377133 November 2042 product 12239689 January 2037 use U-4425 12156917 January 2037 use U-4425 10835578 January 2037 substance, product 11154593 January 2037 substance, product 12083182 January 2037 use U-4425 11311604 January 2037 substance, product 11389511 January 2037 product 11224661 January 2037 substance, product 11413351 January 2037 substance, product 11389510 January 2037 substance, product 8906847 April 2031 substance, product
Regulatory exclusivity Code Expires ODE-516 February 2033 NCE February 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.